PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

Ensartinib has shown efficacy in ALK+ NSCLC patients previously treated with crizotinib and/or next generation ALK inhibitors (ALKi). This clinical benefit is associated with high intracranial (IC) activity in patients with brain metastases and a favorable safety profile. We report updated data in pre-treated NSCLC cohorts from the eXalt2 study. eXalt2 is an ongoing multicenter Phase I/II study. We report data on patients treated with ensartinib...